CRL · News · 20260805N

Market Demand Trends

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 17 · Surprise 24

Charles River reported improving demand for drug discovery and development services, particularly from biotechnology clients. The Discovery and Safety Assessment (DSA) segment showed a strong recovery, with improved order trends, backlog, and book-to-bill activity. Demand was described as strengthening among both small and mid-sized biotechnology companies and global biopharmaceutical clients.

Key facts

• CRL stock jumped 11.4% following strong Q2 non-GAAP earnings and lifted full-year guidance. source
• The stock's 1-year price return was 39.78% and the 6-month gain was 27.45% as reported when it hit $266.00. source
• Management said the raised full-year guidance was driven by improving demand in its DSA (Discovery and Safety Assessment) segment and strong performance in Manufacturing. source
• Company said it was seeing a strong demand recovery in the DSA segment. source
• Charles River stock reached a 52-week high of $266.00, surpassing its previous high of $242.73, and had a market capitalization of $11.28 billion. source